Shots:
- The US FDA has approved Guardant360 CDx as a companion diagnostic to identify pts with ESR1mutations in ER+, HER2- advanced or metastatic breast cancer who may benefit from treatment with Arvinas’ Veppanu (vepdegestrant)
- Approval was supported by clinical data showing that Guardant360 CDx, a non-invasive liquid biopsy test, demonstrated clinical utility in identifying ESR1 mutations to guide treatment selection in ER+/HER2- advanced breast cancer
- Guardant360 CDx is a liquid biopsy for comprehensive genomic profiling, detecting multiple genomic alterations across solid tumors & approved as a companion diagnostic for therapies in NSCLC, breast cancer, & colorectal cancer
Ref: Businesswire | Image: Guardant Health | Press Release
Related News: Guardant Health and Nuvalent Partner on Precision Oncology Diagnostics
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
